Other
Disease Progression
0
Pipeline Programs↗
5
Active Trials↗
3
Companies Involved↗
Disease Progression is an early-stage landscape with 0 programs across 3 companies. The most active players are Qidong Gaitianli Medicines Co., Ltd, Teva, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
16
clinical trials
Completed7 · 44%
Terminated3 · 19%
Recruiting2 · 13%
Suspended1 · 6%
Not yet recruiting1 · 6%
Enrolling by invitation1 · 6%
Other1 · 6%
Clinical Trials
Trial Activity
16 trials
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
Recruiting·—·Phase 2·NCT06652048·60 enrolled
Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2
Active, not recruiting·—·Phase 1/2·NCT05152914·5 enrolled
Longitudinal Imaging Biomarkers of Disease Progression in DLB
Enrolling by invitation·—·Phase 4·NCT03582488·135 enrolled
A Study of Disease Progression and Anti-HIV Treatments
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001068·210 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)